United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
United Therapeutics Corp. is conducting a Phase 3 study titled ‘A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients.’ The study aims to evaluate the efficacy and safety of the drug Ralinepag, when added to standard care or specific background therapy, in patients with WHO Group 1 Pulmonary Arterial Hypertension (PAH). This study is significant as it could potentially improve treatment outcomes for PAH patients.
The intervention being tested is Ralinepag, an oral extended-release tablet, designed to enhance treatment for PAH. It is compared against a placebo to assess its effectiveness and safety.
The study is interventional, with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are blinded. The primary purpose of the study is treatment-focused.
The study began on August 30, 2018, with primary completion expected by June 23, 2025. The last update was submitted on June 23, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the study’s progress and eventual results.
This update could influence United Therapeutics’ stock performance positively, as successful outcomes may enhance their market position in the PAH treatment space. Investors should also consider the competitive landscape, as advancements in PAH therapies could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.